Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Baird Maintains Outperform on Homology Medicines, Lowers Price Target to $9

Baird analyst Madhu Kumar maintains Homology Medicines (NASDAQ:FIXX) with a Outperform and lowers the price target from $10 to $9.
byBenzinga Newsdesk
August 31, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Baird analyst Madhu Kumar maintains Homology Medicines (NASDAQ:FIXX) with a Outperform and lowers the price target from $10 to $9.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts